Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06389591 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

Study acronym: ASPIRE
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Site details revised Show 1 more changeShow less
    • Site details revised
  2. Eligibility criteria expanded, about 45 words Publications: details revised at 1 of 1 entry Show 1 more changeShow less
    • Publications: details revised at 1 of 1 entry
  3. Trial status changed: Active, Not Recruiting → Recruiting Site details revisedv13 Show 1 more changeShow less
    • Site details revised
  4. Eligibility criteria expanded, about 8 wordsv12 See this version in full on ClinicalTrials.gov ↗
  5. Trial status: Recruiting to Active, Not Recruiting Site details revisedv11 Show 1 more changeShow less
    • Site details revised
Show 9 earlier versionsHide 9 earlier versions
  1. Eligibility criteria shortened, about 8 words Study description shortened, about 31 words · Study arms: 2 to 1v10 Show 2 more changesShow less
    • Study description shortened, about 31 words
    • Study arms: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  2. Site contact updatedv9
  3. Trial status: Active, Not Recruiting to Recruiting Site details revisedv8 Show 1 more changeShow less
    • Site details revised
  4. Primary completion date: Dec 1, 2027 to Dec 1, 2026 Completion date: Dec 1, 2028 to Dec 1, 2027v7 Show 1 more changeShow less
    • Completion date: Dec 1, 2028 to Dec 1, 2027
  5. Start date: Oct 29, 2024 to Dec 2, 2024 Primary completion date: Dec 2027 to Dec 1, 2027 · Completion date: Dec 2028 to Dec 1, 2028v6 Show 2 more changesShow less
    • Primary completion date: Dec 2027 to Dec 1, 2027
    • Completion date: Dec 2028 to Dec 1, 2028
  6. Trial status: Recruiting to Active, Not Recruiting Site details revisedv5 Show 1 more changeShow less
    • Site details revised
  7. Re-verified, no change to tracked fieldsv4
  8. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2024 to Oct 29, 2024 · Eligibility criteria expanded, about 19 words · Study description expanded, about 141 words · 1 morev3 Show 4 more changesShow less
    • Start date changed from estimate of Dec 2024 to Oct 29, 2024
    • Eligibility criteria expanded, about 19 words
    • Study description expanded, about 141 words
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  9. Collaborators expanded, about 4 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
Trial Details
NCT Number NCT06389591
Lead Sponsor University of Florida
Collaborators: National Cancer Institute (NCI)
Conditions Recurrent Glioblastoma
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov